Financing (Tables)

12 Months Ended

Dec. 31, 2021

Debt Disclosure [Abstract]

Components Of Debt

The components of the Company’s debt as of December 31 were as follows (amounts in millions):

	Outstanding Amount
Description and Aggregate Principal Amount	2021		2020
U.S. dollar-denominated commercial paper	$	1,440	$	—
Euro-denominated commercial paper (€1.2 billion and €500 million, respectively)	1,366		611
Zero-coupon LYONs due 1/22/2021	—		24
0.352% senior unsecured notes due 3/16/2021 (¥30.0 billion) (the “2021 Yen Notes”)	—		290
Floating rate senior unsecured notes due 6/30/2022 (€250 million) (the “Floating Rate 2022 Euronotes”)	284		305
2.05% senior unsecured notes due 11/15/2022 (the “2022 Biopharma Notes”)	699		698
0.5% senior unsecured bonds due 12/08/2023 (CHF 540 million) (the “2023 CHF Bonds”)	592		611
1.7% senior unsecured notes due 3/30/2024 (€900 million) (the “2024 Euronotes”)	1,021		1,096
2.2% senior unsecured notes due 11/15/2024 (the “2024 Biopharma Notes”)	698		697
2.5% senior unsecured notes due 7/08/2025 (€800 million) (the “2025 Euronotes”)	—		975
3.35% senior unsecured notes due 9/15/2025 (the “2025 U.S. Notes”)	498		498
0.2% senior unsecured notes due 3/18/2026 (€1.3 billion) (the “2026 Biopharma Euronotes”)	1,416		1,520
2.1% senior unsecured notes due 9/30/2026 (€800 million) (the “2026 Euronotes”)	907		975
0.3% senior unsecured notes due 5/11/2027 (¥30.8 billion) (the “2027 Yen Notes”)	267		297
1.2% senior unsecured notes due 6/30/2027 (€600 million) (the “2027 Euronotes”)	680		729
0.45% senior unsecured notes due 3/18/2028 (€1.3 billion) (the “2028 Biopharma Euronotes”)	1,413		1,518
1.125% senior unsecured bonds due 12/08/2028 (CHF 210 million) (the “2028 CHF Bonds”)	233		241
2.6% senior unsecured notes due 11/15/2029 (the “2029 Biopharma Notes”)	795		795
2.5% senior unsecured notes due 3/30/2030 (€800 million) (the “2030 Euronotes”)	910		978
0.75% senior unsecured notes due 9/18/2031 (€1.8 billion) (the “2031 Biopharma Euronotes”)	1,980		2,127
0.65% senior unsecured notes due 5/11/2032 (¥53.2 billion) (the “2032 Yen Notes”)	461		514
1.35% senior unsecured notes due 9/18/2039 (€1.3 billion) (the “2039 Biopharma Euronotes”)	1,406		1,511
3.25% senior unsecured notes due 11/15/2039 (the “2039 Biopharma Notes”)	890		889
4.375% senior unsecured notes due 9/15/2045 (the “2045 U.S. Notes”)	499		499
1.8% senior unsecured notes due 9/18/2049 (€750 million) (the “2049 Biopharma Euronotes”)	844		907
3.4% senior unsecured notes due 11/15/2049 (the “2049 Biopharma Notes”)	889		889
2.6% senior unsecured notes due 10/01/2050 (the “2050 U.S. Notes”)	980		979
2.8% senior unsecured notes due 12/10/2051 (the “2051 U.S. Notes”)	983		—
Other	25		31
Total debt	22,176		21,204
Less: currently payable	(8)		(11)
Long-term debt	$	22,168	$	21,193

The following summarizes the key terms of the offerings in aggregate ($ in millions):

	Issue Date	Aggregate Principal Amount		Stated Annual Interest Rate		Issue Price (as % of Principal Amount)		Maturity Date	Interest Payment Dates (in arrears)
2051 U.S. Notes	December 10, 2021	$	1,000	2.8	%	99.396	%	December 10, 2051	June 10 and December 10

Schedule of Maturities of Long-term Debt

The Company’s minimum principal payments for the next five years are as follows ($ in millions):

2022	$	8
2023	4,367
2024	1,710
2025	490
2026	2,323
Thereafter	13,278